Current filters:


Popular Filters

6710 to 6734 of 6948 results

PTC Therapeutics and Genzyme restructuring ataluren collaboration


Privately-held PTC Therapeutics and fellow USA-based Genzyme, now part of French drug major Sanofi (Euronext:…

atalurenGenzymeLicensingPharmaceuticalPTC TherapeuticsRare diseasesSanofi

Japan’s Toyobo to increase capacity for injectables, eyeing biosimilars


Japanese conglomerate Toyobo (TYOO: 3101) has outlined plans for its biosciences segment, which includes…

Asia-PacificBiotechnologyFinancialMarkets & MarketingPharmaceuticalToyobo

French medical-imaging market worth 800 million euros


Medical imaging is an extremely open and dynamic sector in France, thanks to government initiatives which…

EuropeMarkets & MarketingPharmaceutical

US FTC long-awaited final report finds brand-name firms use leverage of authorized generic entry to delay competition


The USA’s Federal Trade Commission this week issued its final report, titled Authorized Generic…

GenericsLegalNorth AmericaPharmaceuticalRegulation

Erbitux and Gilenya added to Australia’s PBS listing


More than 400,000 Australians will benefit from new subsidized medicines, effective September 1, as Minister…

Asia-PacificErbituxGilenyaMerck KGaANeurologicalNovartisOncologyPharmaceuticalPricingRegulation

Roche’s Tarceva Oked in EU for first-line use in a genetically distinct type of lung cancer


Swiss drug major Roche (ROG: SIX) says that the European Commission has approved Tarceva (erlotinib)…


Executive changes at Onyx Pharma and XOMA


Onyx Pharmaceuticals (Nasdaq: ONXX) has appointed Helen Torley as executive vice president and chief…

ManagementOnyx PharmaceuticalsPharmaceuticalXOMA Corp

PCMA outlines $100 billion in Rx drug savings in USA


As the USA’s Joint Select Committee on Deficit Reduction examines options to reduce the deficit…

BiotechnologyGenericsHealthcareNorth AmericaPharmaceuticalPricingRegulation

RUBY-1 trial shows Astellas’ blood thinner darexaban increases bleeding


A Phase II dose-finding study has found that the new oral Factor Xa inhibitor darexaban, under development…

Astellas PharmaCardio-vasculardarexabanPharmaceuticalResearch

UCB presents new data on Vimpat and health care costs associated with epilepsy at IEC meeting


Consistent evidence that adjunctive treatment with epilepsy drug Vimpat (lacosamide) was generally well…


Astellas files for OAB drug mirabegron in USA and Europe


Japanese drug major Astellas Pharma (TYO: 4503) says it has submitted a New Drug Application and Market…

Astellas PharmaBetanisGastro-intestinalsmirabegronPharmaceuticalRegulation

Sinclair IS in Episil licensing deal with Teva


UK-based specialty drugmaker Sinclair IS Pharma (AIM: SPH.L) has signed a license agreement with Israel’s…

EpisilLicensingNeurologicalOncologyPharmaceuticalSinclair IS PharmaTeva Pharmaceutical Industries

Pfizer’s Pristiq sees private plan formulary access similar to Lilly’s Cymbalta


In the USA, similar percentages of private health plan lives have formulary access to Pfizer’s (NYSE:…

CymbaltaEli LillyHealthcareNeurologicalNorth AmericaPfizerPharmaceuticalPricingPristiq

Long-term outlook and predictability key to successful medicines policy for Australia, conference told


A predictable regulatory and reimbursement environment, and a long-term policy outlook are essential…


Limited growth forecast for Singapore pharmaceuticals industry by BMI


Singapore is a low-risk pharmaceutical market, propped up by pro-business policies, well developed health…

Asia-PacificHealthcareMarkets & MarketingPharmaceutical

Valeant out-bids Paladin with C$76 million cash bid for Afexa


Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says that it has entered…

Afexa Life SciencesMergers & AcquisitionsPaladin LabsPharmaceuticalValeant Pharmaceuticals

Public Citizen petitions US FDA to amend generic drug labeling regulations in the wake of Mensing


The US Food and Drug Administration should revise its regulations to allow generic drug manufacturers…

GenericsNorth AmericaPharmaceuticalRegulation

Eisai updates on epilepsy drugs Zonegran, Zebinix and perampanel at IEC


Japanese drug major Eisai (TYO: 4523) presented new data at the International Epilepsy Congress taking…


US FDA stalls Novartis Ilaris approval for gouty arthritis, calling for more clinical data


There was a big disappointment, albeit not unexpected, for Swiss drug major Novartis (NOVN: VX) when…

Anti-Arthritics/RheumaticsIlarisNorth AmericaNovartisPharmaceuticalRegulation

6710 to 6734 of 6948 results

Back to top